Author: aveak

10 Sep

Posted at 12:13h in Press Releases by
0 Likes

Consano Bio, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to C-1101, the Company's lead investigational, platelet-derived biologic for the treatment of chronic, painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. Presently, there are no FDA-approved pharmaceutical...

18 Aug

Posted at 09:15h in Press Releases by
0 Likes

Consano Bio, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to C-1101, the Company's lead investigational, platelet-derived biologic for the treatment of chronic, painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. Presently, there are no FDA-approved pharmaceutical...

20 Jul

Posted at 07:15h in Press Releases by
0 Likes

Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101, the company’s potential first-in-class, disease-modifying, non-opioid therapy...

29 Jun

Posted at 08:03h in Press Releases by
0 Likes

Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101, the company’s potential first-in-class, disease-modifying, non-opioid therapy...

26 May

Posted at 14:02h in Press Releases by
0 Likes

Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today announced that the first patient has been successfully dosed in its first Phase 1 clinical trial (C-1101-101, NCT07264270) evaluating C-1101 in patients with chronic, painful lumbosacral radiculopathy...

19 Nov

Posted at 09:24h in Press Releases by
0 Likes

Consano Bio today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College...